Linfoma No-Hodgkin: empleo de emisores gamma para su diagnóstico
DOI:
https://doi.org/10.35954/SM2015.34.1.7Palabras clave:
Cáncer; Emisores Gamma; Linfoma No Hodgkin; PositronesResumen
El 24,8% de las muertes en Uruguay se deben a cáncer. El linfoma no Hodgkin (LNH) es la neoplasia hematológica más frecuente y quinta causa de muerte por cáncer en el mundo, más del 90% tiene origen en linfocitos B y expresan el antígeno CD20. El anticuerpo monoclonal Rituximab® reconoce con alta afinidad a dicho antígeno de superficie y es empleado en el tratamiento del LNH CD20 positivo. Actualmente, además del Rituximab® se encuentra aprobado por la FDA el uso del anticuerpo anti-CD20 asociado con emisores beta (1311, 90Y), los cuales potencian su efecto e incrementan su efectividad terapéutica
En el presente trabajo se pretende demostrar que el desarrollo de nuevos agentes de imagen empleando anticuerpos monoclonales dirigidos contra blancos específicos de superficie celular y unidos a emisores gamma convencionales o emisores de positrones permitiría mejorar la sensibilidad y especificidad de la Imagenología para la estatificación de esta patología.
Recibido para evaluación: Marzo 2015
Aceptado para publicación: Junio 2015
Correspondencia: Laboratorio de Radiofarmacia, Centro de lnvestigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica. Mataojo 2055, C.P. 11400, Montevideo, Uruguay. Tel.: (+598)25250901/108; fax: (+598)25250895.
E-mail de contacto: pcabral@cin.edu.uy
Descargas
Métricas
Citas
(1) Alexander D, Mink J, Adami O, Chang T, Cole P, Mandel J, et.al. The non-Hodgkin lymphomas: A review of the epidemiologic literature. Int J Cancer 2007; 120(S12):1-39.
(2) Australian Institute of health and welfare and australasian association of cancer regitries. Cancer in Australia. Canberra: Australian Institute of Health and welfare, 2003
(3) Vassallo J, Barrios E. Actualización Ponderada de los Factores de Riesgo del Cáncer. Montevideo: Comisión Honoraria de Lucha contra el Cáncer, 2003.
(4) Rivera R, Martinez R, Borrego R, Lanche T. Linfoma no Hodgkin de niño, Comparacion de dos protocolos de quimioterapia. Revista del Instituto Nacional de Cancerología 1987; 33(1). Disponible en: http://www.incan.org.mx/revistaincan/index.php?id=1247529194 [Consulta 09/06/2015].
(5) Rosenberg A. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Cancer Treat Rep 1977; 61(6):1023-1027.
(6) Anderson J, Armitage O, Berger F, Cavalli F, Chan C, Close J, et.al. A clinical evaluation of the International Lymphoma Study Group classification of Non-Hodgkin's Lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 88(11):3909-3918.
(7) Lichtman M, Kipps T, Seligsohn U, Kaushansky K, Prchal J. Williams Hematology. 7th.ed. New York : McGraw-Hill Medical, 2006.
(8) Jaffe E, Harris N, Stein H, Vardiman J, ed. World Health Organization Classification of tumor. Pathology and genetics of Tumor of Haematopoietic and Lymphoid Tissues. Lyon : IARC PRESS, 2001.
(9) Tedder F, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15(9):450-4.
(10) Deghiedy H, Fouda M, Shahin D, Shamaa S, El-Bedewy A, Abd El-Ghaffar H. Diagnostic and prognostic utility of t(14;18) in follicular lymphoma. Acta Haematol 2007; 118(4):231-236.
(11) Einfeld A, Brown P, Valentine A, Clark A, Ledbetter A. Molecular cloning of the human cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1998; 7(3):711-17.
(12) Valentine A, Meier E, Rossie S, Clark A. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase. C J Biol Chem 1989; 264(19):11282-11287.
(13) Tedder F, Boyd W, Freedman S, Nadler M, Schlossman F. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985; 135(2): 973-979.
(14) Sieber T, Schoeler D, Ringel F, Pascu M, Schriever F. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukemia cells. Br J Haematol 2003; 121(3):458-461.
(15) Cragg S, Walshe A, Ivanov O, Glennie J. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140-174.
(16) McLaughlin P, Grillo-López J, Link K, Levy R, Czuczman S, Williams E, et.al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8):2825-2833.
(17) Hanson C, Kurtin P, Katzmann J, Hoyer D, Li Y, Hodnefield M, et.al. Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood 1999; 94(11):3389-3896.
(18) London K, Cross S, Onikul E, Dalla-Pozza L, Howman-Giles R. 18F-FDGPET/CT in pediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imag 2011; 38(2):274-284.
(19) Olafsen T, Betting D, Kenanova E, Salazar B, Clarke P, Said J, et.al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 2009; 50(9):1500-8.
(20) Weiler-Sagie M, Bushelev O, Epelbaum R, Dann J, Haim N, Avivi I, et.al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010; 51(1):25-30.
(21) Gómez R, González Y, Dita M, Fernández J, Espinosa E, Arencibia A. Tumor de la órbita como forma poco común de presentación de un linfoma no hodgkiniano extranodal de la zona marginal. Rev Cubana Hematol Inmunol Hemoter 2010; 26(1):76-82.
(22) McLaughlin P, Grillo-López J, Link K, Levy R, Czuczman S, Williams E, et.al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8): 2825-2833.
(23) Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et.al. CHOP chemotherapy plus rituximab comprared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4):235:242.
(24) Johnson P, Glennie M. The mechanisms of action of rituximab in elimination of tumor cells. Semin Oncol 2003; 30(1):3-8.
(25) Golay J, Gramigna R, Facchinetti V, Capello D, Gaidano G, Introna M. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 2002; 119(4):923-929.
(26) Cragg S, Walshe A, Ivanov O, Glennie J.The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140-174.
(27) Coffey J, Hodgson D, Gospodarowicz M. Therapy of non Hodgkin´s lymphoma. Eur J Nucl Med Mol Imaging 2003; 30(1):S28-S36.
(28) Gopal A, Press O. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999; 134(5):445-450.
(29) Tallman M. Monoclonal antibody therapies in leukemias. Semin Hematol 2002; 39(4):12-19.
(30) Withoff S, Bijman A, Stel J, Delahaye L, Calogero A, De Jonge M, et.al. Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells. Br J Cancer 2001; 84(8):1115-1121.
(31) Avivi I, Robinson S, Golgstone A. Clinical use of rituximab in haematological malignancies. Minireview. Br J Cancer 2003; 89(8):1389-1394.
(32) Johnson P, Glennie M. Rituximab: mechanisms and application. Br J Cancer 2001; 85(11):1619-1623.
(33) Emmanouilides C. Radioimmunotherapy for non-hodgkin lymphoma : historical perspective and current status. J Clin Exp Hematop 2007; 47(2):43-60.
(34) Kaminski S, Zasadny R, Francis R, Milik W, Ross W, Moon D, et.al. Radioimmunotherapy of B-cell lymphoma with (131I)anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329(7):459-465.
(35) DeNardo J, DeNardo L, O'Grady L, Macey J, Mills L, Epstein L, et.al. Tratment of a patient with B-cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers 1987; 2(1):49-53.
(36) Palanca-Wessels C, Press O. Improving the Efficacy of Radioimmunotherapy for Non-Hodgkin’s Lymphomas. Cancer 2010; 116(4 Suppl): 1126-1133.
(37) DeNardo L, DeNardo J, O'Grady F, Levy B, Adams P, Mills L. Fractionated radioimmunotherapy of B-cell malignancies with I-131 Lym-1. Cancer Res 1990; 50(3 suppl.): 1014S-1016S.
(38) DeNardo J, DeNardo L, O'Grady F, Hu E, Sytsma M, Mills L, et.al. Treatment of B-cell malignancies with I-131 Lym-1 monoclonal antibodies. Int J Cancer 1988; 41(S3):96-101.
(39) Denardo L, Lewis P, Denardo J, O'Grady F. Effects of Lym-1 radioimmunoconjugated on refractory chronic lymphocytic leukemia. Cancer 1994; 73(5):1425-1432.
(40) DeNardo L, DeNardo J, Goldstein S, Kroger A, Lamborn R, Levy N, et.al. Maximun tolerated dose, toxicity and efficacy of I-131 Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin lymphoma. J Clin Oncol 1998; 16(10):3246-3256.
(41) McKinney M, Beaver A. Yttrium-90 ibiritumomab tioxetan in the treatment of non-Hodgkin lymphoma. Blood and lymphatic Cancer: Targets and therapy 2014; 4:45-59.
(42) Dillman R. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin Exp Med 2006; 6(1):1-12.
(43) Goldengerg D. The role of radiolabeled antibodies in the treatment of non-Hodgkin’s lymphoma: the coming of age of radioimmunotherapy. Critical Reviews in Oncology/Hematology 2001; 39(1):195-201.
(44) Oliver P, Robles M, Trinidade V, Cabral P, Tortarolo V, Nappa A, et.al. Labelling and biological valuation of anti-CD-20 for treatment of non-Hodgkin's lymphoma. Nucl Med Rev 2005; 8, Suppl. A:16.
(45) Audicio P, Castellano G, Tassano M, Rezzano M, Fernandez M, Riva E, at.al. [177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies. Appl Radiat Isot 2011; 69(7):924-8.
(46) Leahy M, Turner J. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 2011; 117(1):45-52.
(47) Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et.al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42.
(48) Juweid M. Radioimmunotherapy of B-Cell Non- Hodgkin’s Lymphoma: From clinical trials to clinical practice. J Nucl Med 2002; 43(11):1507-29.
(49) Whal R, Kroll S, Zasadny K. Patient specific whole body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med 1998; 39(8):14S-20S.
(50) Kaminski M, Zasadny K, Francis I, Milik A, Ross C, Moon S, et.al. Radioimmunotherapy of Bcell lymphoma with 131Ianti-B1 (antiCD20) antibody. N Engl J Med 1993; 329(7):459-65.
(51) Knox S, Goris M, Trisler K, Negrin R, Davis T, Liles T, et.al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Can Res 1996; 2(3):457-70.
(52) Buchsbaum D, Wahl R, Glenn S, Normolle D, Kaminski M. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res 1992; 52(3):637-42.
(53) Dillman R, Shawler D, Sobol R, Collins H, Beauregard J, Wormsley S, et.al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood, 1982; 59(5):1036-1045.
(54) Reff M, Carner, K, Chambers K, Chinn P, Leonard J, Raab R, et.al. Depletion of B cell in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83(2):435-45.
(55) Wiseman G, White C, Stabin M, et.al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000; 27:766-77.
(56) Wiseman G, White C, Sparks R, Erwin W, Podoloff D, Lamonica D, et.al. Biodistribution and dosimetry results from a phase III prospectively randomized control trial of ZevalinTM radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 2001; 39(1):181-94.
(57) Ferro-Flores G, Torres-García E, García-Pedroza L, Arteaga de Murphy C, Pedraza-López M, Garnica-Garza H. An efficient, reproducible and fase preparation of 188Re-anti-CD20 for the treatment of non-Hodgkin´s lymphoma. Nucl Med Communications 2005; 26(9):793-99.
(58) Knop S, Jakob A, Kanz L, Hebart H, Bares R, Dohmen B. 186Rhenium labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2004; 103(3):1175.
(59) Marcus R, Imrie K, Solal-Celigny P, Catalano J, Dmoszynska A, Raposo J, et.al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26(28):4579-86.
(60) Dietlein M, Pels H, Schulz H, Staak O, Borchmann P, Schomäcker K, et.al. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol 2005; 74(4):348-52.
(61) Melhus K, Larsen R, Stokke T, Kaalhus O, Selbo P, Dahle J. Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th. Cancer Biotherm Radiopharm 2007; 22(4):469-79.
(62) Dias C, Jeger S, Osso J, Müller C, De Pasquale C, Hohn A, et.al. Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology. Nucl Med Biol 2011; 38(1):19-28.
(63) Malviya G, Anzola K, Podestà E, Laganà B, Del Mastro C, Dierckx R, et.al. 99mTc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients. Mol Imaging Biol 2012; 14(5):637-46.
(64) Pandey U, Kameswaran M, Dev Sarma H, Samuel G. 99mTc carbonyl DTPA–Rituximab: Preparation and preliminary bioevaluation. Appl Radiat Isot 2014; 86:52-6.
(65) Mankoff D. A definition of molecular imaging. J Nucl Med 2007; 48(6):18N-21N.
(66) Phelps M. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000; 41(4):661-81.
(67) Meikle S, Kench P, Kassiou M, Banati R. Small animal SPECT and its place in the matrix of molecular imaging technologies. Phys Med Biol 2005; 50(22):R45-61
(68) Urbain J, Vekemans M, Lemieux S, Cosenza S, Senadhi V, Milestone B, et.al. Nuclear oncology and the imagine concept. Acta Radiol Suppl 1997; 412:21-8.
(69) Reilly R. Immunoscintigraphy of tumours using Tc labelled monoclonal -antibodies: a review. Nucl Med Commun 1993; 14:34-59.
(70) Mather S. Radiolabelled antibodies and peptides. En: Sampson C, editor. Textbook of radiopharmacy theory and practice. 3a.ed. New York : Gordon and Breach Science Publishers, 1990. p.63-82.
(71) Rennen H, Boerman O, Koenders E, Oyen W, Corstens F. Labeling proteins with Tc-99m via Hydrazinonicotinamide (HYNIC): Optimization of the conjugation reaction. Nucl Med Biol 2000; 27(6):599-604.
(72) Jurisson S, Berning D, Jia W, Ma D. Coordination compounds in nuclear medicine. Chemical Reviews 1993; 93(3):1137-1156.
(73) Olafsen T, Betting D, Kenanova V, Salazar F, Clarke P, Said J, et.al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 2009; 50(9):1500-08.
(74) Wu A, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J 2008; 14(3):191-97.
(75) Zimmermann K, Gianollini S, Schubiger P, Novak-Hofer I. A triglycine linker improves tumor uptake and biodistributions of 67-Cu-labeled anti-neuroblastoma MAb chCE7 F(ab9)2 fragments. Nucl Med Biol 1999; 26(8):943-50.
(76) Sundaresan G, Yazaki P, Shively J, Finn R, Larson S, Raubitschek A, et.al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003; 44(12):1962-69.
(77) Wu A, Yazaki P, Tsai S, Nguyen K, Anderson A, McCarthy, et.al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA 2000; 97(15):8495-8500.
Publicado
Cómo citar
Número
Sección
Licencia
Hasta 2024 utilizamos la licencia Creative Commons Atribución/Reconocimiento-NoComercial 4.0 Internacional https://creativecommons.org/licenses/by-nc/4.0/deed.es. La cual dice que: usted es libre compartir, copiar y redistribuir el material en cualquier medio o formato, también de adaptar, remezclar, transformar y construir a partir del material. Bajo los siguientes términos:
- Atribución: usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios . Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
- NoComercial: usted no puede hacer uso del material con propósitos comerciales .
A partir de 2025 los autores conservan sus derechos de autor y ceden a la revista el derecho de primera publicación de su obra, el cual estará simultáneamente sujeto a la licencia https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es que permite compartir, copiar y redistribuir el material en cualquier medio o formato siempre que se indique la publicación inicial en esta revista. Adaptar, remezclar, transformar y construir a partir del material. Si remezcla, transforma o crea a partir del material, debe distribuir su contribución bajo la la misma licencia del original y no puede hacer uso del material con propósitos comerciales.
Bajo los siguientes términos:
1. Atribución: usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
2. NoComercial: usted no puede hacer uso del material con propósitos comerciales.
3. CompartirIgual: si remezcla, transforma o crea a partir del material, debe distribuir su contribución bajo la la misma licencia del original.
PlumX Metrics
.png)
